Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 7/20 | 0.64 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.49 |
| ▸ | MLYCD | O95822 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675994 | 0.85 | CA1 (0.64) | NR1H4TRPV1HDAC3HDAC11HDAC8 | |
| SCHEMBL5293330 | 0.85 | DHODH (0.52) | NR1H4TRPV1MEN1KMT2AKIF11 | |
| SCHEMBL13676191 | 0.85 | MEN1 (0.61) | NR1H4TRPV1SMN1; SMN2LMNAMAPT | |
| SCHEMBL13676146 | 0.85 | TRPV1 (0.62) | NR1H4TRPV1HDAC3HDAC11HDAC8 | |
| SCHEMBL13675964 | 0.85 | TRPV1 (0.62) | NR1H4TRPV1HDAC3HDAC11HDAC8 | |
| SCHEMBL13675963 | 0.85 | TRPV1 (0.62) | NR1H4TRPV1EPHX2HDAC3HDAC11 | |
| SCHEMBL13676192 | 0.85 | TRPV1 (0.62) | NR1H4TRPV1EPHX2HDAC3HDAC11 | |
| SCHEMBL13676000 | 0.85 | TRPV1 (0.62) | NR1H4TRPV1EPHX2HDAC3HDAC11 | |
| SCHEMBL13676145 | 0.83 | TRPV1 (0.60) | NR1H4TRPV1HDAC3HDAC11HDAC8 | |
| SCHEMBL5286169 | 0.83 | TRPV1 (0.60) | NR1H4TRPV1EPHX2HDAC3HDAC11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. | 2009-10-22 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582657-B2 | Treating inflammatory and neuropathic pain, headache, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, eye disorders, bladder disorders, psoriasis, skin disorders, asthma, herpes simplex | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579347-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264424-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | NR1H4 290/4885TRPV1 1/4885EPHX2 4360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.